

Camroid

(Piroxicam-Beta-Cyclodextrin)

20 mg Tablet

کیمرائیڈ ٹیبلیٹس
۲۰ ملی گرام

Warning:

Absolute contraindications:

Not to be given to those patients who have history of:

- ✓ **Stroke: Cerebrovascular accident, CVA**
- ✓ **Heart attack: Myocardial infarction, MI**
- ✓ **Coronary artery bypass graft: CABG**
- ✓ **Uncontrolled hypertension**
- ✓ **Congestive heart failure (CHF), NYHA II-IV**


1.0 PHARMACOLOGIC CATEGORY

Non-steroidal Anti-inflammatory Drug (NSAID)

2.0 DESCRIPTION

Piroxicam (Feldene Flash) is 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1, 2-benzothiazine-3- carboxamide 1,1-dioxide, an oxicam. Members of the oxicam family are not carboxylic acids, but they are acidic by virtue of the enolic 4-hydroxy substituent. Piroxicam (Feldene Flash) occurs as a white crystalline solid, sparingly soluble in water, dilute acid and most organic solvents. It is slightly soluble in alcohols and in aqueous alkaline solution. It exhibits a weakly acidic 4-hydroxy proton (pKa 5.1) and weakly basic pyridyl nitrogen (pKa 1.8).

Molecular Formula: C₁₅H₁₃N₃O₄S. Molecular Weight: 331.35.



3.0 FORMULATION/COMPOSITION

Each tablet contains 20 mg Piroxicam
(As per innovator's Specification)

4.0 Dosage and Method of Administration

Undesirable effects may be minimized by using the minimum effective dose for the shortest duration necessary to control symptoms.

Dosage

Rheumatoid Arthritis, Osteoarthritis (Arthrosis, Degenerative Joint Disease), Ankylosing Spondylitis

The recommended starting dose is 20 mg given as a single daily dose. The majority of patients will be maintained on 20 mg daily. A relatively small group of patients may be maintained on 10 mg daily.

Acute Gout

Because of its GI safety profile piroxicam (Feldene Flash) should not be used in first-line treatment for acute gout when an NSAID is indicated. For the same reason, it should not be used to treat acute gout in patients most at risk of developing serious GI adverse events. Therapy should be initiated by a single dose of 40 mg, followed on the next 4 to 6 days with 40 mg daily, given in single or divided doses. Piroxicam (Feldene Flash) is not indicated for the long term management of gout.

Acute Musculoskeletal Disorders

Because of its GI safety profile piroxicam (Feldene Flash) should not be used in first-line treatment for acute musculoskeletal disorders when an NSAID is indicated. For the same reason, it should not be used to treat acute musculoskeletal disorders in patients most at risk of developing serious GI adverse events. Therapy should be initiated with 40 mg daily for the first two days given in single or divided doses. For the remainder of the 7 to 14 day treatment period, the dose should be reduced to 20 mg daily.

Post-operative and Post-traumatic Pain

The recommended dose is 20 mg, given as a single daily dose.

Dysmenorrhea

Because of its GI safety profile piroxicam (Feldene Flash) should not be used in first-line treatment for dysmenorrhea when an NSAID is indicated. For the same reason, it should not be used to treat dysmenorrhea in patients most at risk of developing serious GI adverse. The treatment of primary dysmenorrhea is initiated at the earliest onset of symptoms with a recommended starting dose of 40 mg given as a single daily dose for the first two days. Treatment may be continued thereafter with a single daily dose of 20 mg for the next one to three days as necessary.

Upper Respiratory Tract Inflammation

The adult dosage is 10 mg or 20 mg orally once daily for five to seven days.

Use in Children

Juvenile Rheumatoid Arthritis (JRA)

The recommended dosages for children with JRA are based on body weight as follows:

<u>Weight (kg)</u>	<u>Dose (mg)</u>
less than 16	5
16 to 25	10
26 to 45	15
greater than 46	20

The drug should be taken once daily.

Administration

Oral

Piroxicam (Feldene Flash) tablets may be swallowed with water, or placed on the tongue to disperse and then swallowed with saliva or water as a suspension. Piroxicam (Feldene Flash) tablet dissolves almost instantly in the mouth in the presence of water or saliva.

Combined Administration

The total daily dosage of Piroxicam (Feldene Flash) administered as fast dissolving tablet should not exceed the maximum recommended daily dosage as indicated above.

4.1 Contraindications

Piroxicam (Feldene Flash) is contraindicated in:

Patients with a history of gastro-intestinal ulceration, bleeding or perforation. Patients with active peptic ulcerations.

Patients with known hypersensitivity to piroxicam (Feldene Flash) or to any of the excipients, namely, gelatin, mannitol, aspartame, citric acid anhydrous, lactose, corn starch, magnesium stearate, and sodium lauryl sulphate. The potential exists for cross sensitivity to aspirin and other NSAIDs. Piroxicam (Feldene Flash) should not be given to patients in whom aspirin and other NSAIDs induce the symptoms of asthma, nasal polyps, angioedema or urticaria.

Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Patients with severe renal and hepatic failure.

Patients with severe heart failure.

4.2 Special Warnings and Precautions for Use

The use of piroxicam (Feldene Flash) with concomitant systemic non-aspirin NSAIDs including cyclooxygenase 2 (COX-2) inhibitors should be avoided. Concomitant use of a systemic NSAID and another systemic NSAID may increase frequency of gastrointestinal ulcers and bleeding.

Cardiovascular Effects

NSAIDs may cause an increased risk of serious cardiovascular (CV) thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. The relative increase of this risk appears to be similar in those with or without known CV disease or CV risk factors. However, patients with known CV disease or CV risk factors may be at greater risk in terms of absolute incidence, due to their increased rate at baseline. To minimize the potential risk for an adverse CV event in patients treated with piroxicam (Feldene Flash), the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV toxicity and the steps to take if they occur.

Hypertension

As with all NSAIDs, piroxicam (Feldene Flash) can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. NSAIDs, including piroxicam (Feldene Flash), should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of therapy with piroxicam (Feldene Flash) and throughout the course of therapy.

Fluid Retention and Edema

As with other drugs known to inhibit prostaglandin synthesis, fluid retention and edema have been observed in some patients taking NSAIDs, including piroxicam (Feldene Flash). Therefore, piroxicam (Feldene Flash) should be used with caution in patients with compromised cardiac function and other conditions predisposing to, or worsened by, fluid retention. Patients with pre-existing congestive heart failure or hypertension should be closely monitored.

Gastrointestinal (GI) Effects

NSAIDs, including piroxicam (Feldene Flash), can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. Administration of doses of greater than 20 mg/day carries an increased risk of gastrointestinal side effects. Evidence from observational studies suggests that piroxicam (Feldene Flash) may be associated with a high risk of serious gastrointestinal toxicity, relative to other NSAIDs. When GI bleeding or ulceration occurs in patients receiving piroxicam (Feldene Flash), the treatment should be withdrawn. Patients most at risk of developing these types of GI complications with NSAIDs are the elderly, patients with CV disease, patients using

concomitant corticosteroids, antiplatelet drugs (such as aspirin), selective serotonin reuptake inhibitors, patients ingesting alcohol or patients with a prior history of, or active, gastrointestinal disease, such as ulceration, GI bleeding or inflammatory conditions. Therefore, piroxicam (Feldene Flash) should be used with caution in these patients.

RenalEffects

In rare cases, NSAIDs may cause interstitial nephritis, glomerulitis, papillary necrosis and the nephrotic syndrome. NSAIDs inhibit the synthesis of renal prostaglandin which plays a supportive role in the maintenance of renal perfusion in patients whose renal blood flow and blood volume are decreased. In these patients, administration of an NSAID may precipitate overt renal decompensation, which is typically followed by recovery to pretreatment state upon discontinuation of NSAID therapy. Patients at greatest risk of such a reaction are those with congestive heart failure, liver cirrhosis, nephrotic syndrome and overt renal disease. Such patients should be carefully monitored while receiving NSAID therapy.

Caution should be used when initiating treatment with piroxicam (Feldene Flash) in patients with severe dehydration. Caution is also recommended in patients with kidney disease.

Because of extensive renal excretion of piroxicam (Feldene Flash) and its biotransformation products lower doses of piroxicam (Feldene Flash) should be considered in patients with impaired renal function, and they should be carefully monitored.

HepaticEffects

Piroxicam (Feldene Flash) can cause fatal hepatitis and jaundice. Although such reactions are rare, if abnormal liver function tests persist or worsen, if clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), piroxicam (Feldene Flash) should be discontinued.

SkinReactions

Serious skin reactions, some of them fatal, including drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs, including piroxicam (Feldene Flash). Patients appear to be at highest risk for these events early in the course of therapy, the onset of the event occurring in the majority of cases within the first month of treatment. Piroxicam (Feldene Flash) should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

Cases of fixed drug eruption (FDE) have been reported with piroxicam. Piroxicam should not be reintroduced in patients with history of piroxicam-related FDE. Potential cross reactivity might occur with other.

OphthalmologicEffects

Because of reports of adverse eye findings with NSAIDs, it is recommended that patients who develop visual complaints during treatment with piroxicam (Feldene Flash) have an ophthalmic evaluation.

PoorMetabolizersofCYP2C9Substrates

Patients who are known or suspected to be poor CYP2C9 metabolizers based on previous history/experience with other CYP2C9 substrates should be administered piroxicam (Feldene Flash) with caution as they may have abnormally high plasma levels due to reduced metabolic.

UsewithOralAnti-coagulants

The concomitant use of NSAIDs, including piroxicam (Feldene Flash), with oral anticoagulants increases the risk of GI and non-GI bleeding and should be given with caution. Oral anticoagulants include warfarin/coumarin-type and novel oral anticoagulants (e.g., apixaban, dabigatran, rivaroxaban). Anticoagulation/INR should be monitored in patients taking a warfarin/coumarin- type anticoagulant.

General

For patients with phenylketonuria: because of its aspartame content, Piroxicam (Feldene Flash) tablets contains phenylalanine 0.140 mg per 20 mg dose.

When used for the relief of pain and inflammation in upper respiratory tract inflammation, it should be remembered that NSAIDs are only a symptomatic therapy. When given to patients with such conditions, appropriate concomitant antibacterial therapy should be considered.

4.3 Fertility, Pregnancy and Lactation

Fertility

Based on the mechanism of action, the use of NSAIDs, including piroxicam (Feldene Flash), may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of NSAIDs, including piroxicam (Feldene Flash), should be considered.

Pregnancy

Although no teratogenic effects were seen in animal testing, the use of piroxicam (Feldene Flash) during pregnancy is not recommended. Piroxicam (Feldene Flash) inhibits prostaglandin synthesis and release through a reversible inhibition of the cyclo-oxygenase enzyme. This effect, as with other NSAIDs has been associated with an increased incidence of dystocia and delayed parturition in pregnant animals when drug administration was continued into late pregnancy. NSAIDs are also known to induce premature closure of the ductus arteriosus in infants. Therefore, piroxicam (Feldene Flash) should be avoided during the third trimester of pregnancy.

Inhibition of prostaglandin synthesis might adversely affect pregnancy. Data from epidemiological studies suggest an increased risk of spontaneous abortion after use of prostaglandin synthesis inhibitors in early pregnancy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss.

If used during second or third trimester of pregnancy, NSAIDs may cause fetal renal dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe cases. Such effects may occur shortly after treatment initiation and are usually reversible upon discontinuation. Pregnant women on piroxicam (Feldene Flash) should be closely monitored for amniotic fluid volume.

Lactation

The presence of piroxicam (Feldene Flash) in breast milk has been determined during initial and long term dosing conditions (52 days). Piroxicam (Feldene Flash) appeared in breast milk at about 1% to 3% of the maternal plasma concentration. No accumulation of piroxicam (Feldene Flash) occurred in milk relative to that in plasma during treatment. Piroxicam (Feldene Flash) is not recommended for use in nursing mothers as the clinical safety has not been established.

4.4 Adverse Reaction

Piroxicam (Feldene Flash) is generally well tolerated. Gastrointestinal symptoms are the most commonly encountered side effects but in most instances do not interfere with the course of therapy.

Objective evaluations of gastric mucosal appearances and intestinal blood loss show that 20 mg/day of piroxicam (Feldene Flash) administered either in single or divided daily doses is significantly less irritating to the gastrointestinal tract than acetylsalicylic acid.

The following table lists adverse drug reactions (ADRs) within each standard System Organ Class (SOC) by decreasing order of medical seriousness or clinical importance.

Table 1. Adverse Drug Reactions

System Organ Class	Adverse Drug Reactions
Blood and lymphatic system disorders	Aplastic anemia*, hemolytic anemia*, anemia*, eosinophilia*, leucopenia*, thrombocytopenia*
Immune system disorders	Anaphylaxis*, serum sickness*
Metabolism and nutrition disorders	Hyperglycemia*, hypoglycemia*, anorexia, fluid retention*
Psychiatric disorders	Depression*, hallucinations*, mental confusion*, mood alterations*, insomnia*, nervousness*, dream abnormalities*
Nervous system disorders	Aseptic meningitis*, paresthesia*, headache, dizziness, somnolence, vertigo
Eye disorders	Blurred vision, eye irritations*, swollen eyes*
Ear and labyrinth disorders	Hearing impairment*, tinnitus
Cardiac disorders	Palpitations
Vascular disorders	Vasculitis*, hypertension*
Respiratory, thoracic and mediastinal disorders	Bronchospasm*, dyspnea*, epistaxis*
Gastrointestinal disorders ^a	Perforation*, ulceration*, pancreatitis*, gastrointestinal bleeding (including hematemesis and melena)*, gastritis*, epigastric distress, nausea, constipation, abdominal discomfort, flatulence, abdominal pain, diarrhea, indigestion, stomatitis, ano-rectal reactions to suppositories presenting as local pain, burning, pruritus and tenesmus and rare instances of rectal bleeding*
Hepatobiliary disorders	Fatal hepatitis*, jaundice*
Skin and subcutaneous tissue disorders ^b	Angioedema*, Stevens-Johnson syndrome*, toxic epidermal necrolysis (Lyell's disease)*, drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)*, vesiculobullous reactions*, dermatitis exfoliative*, erythema multiforme*, photoallergic reactions*, fixed drug eruption*, non-thrombocytopenic purpura (Henoch- Schoenlein)*, onycholysis*, alopecia*, skin rash, urticaria*, pruritus
Renal and urinary disorders	Renal failure*, nephrotic syndrome*, glomerulonephritis*, interstitial nephritis*
Reproductive system and breast disorders	Female fertility decreased*
General disorders and administration site conditions	Local adverse reactions (burning sensations) or tissue damage (sterile abscess formation, fatty tissue necrosis) at the site of injection*, malaise*, edema (mainly of the ankle), transient pain upon injection*
Investigations	Reversible elevations of BUN, reversible elevations of creatinine, decreases in hemoglobin and hematocrit unassociated with obvious gastrointestinal bleeding*, increased serum transaminase levels, positive ANA*, weight increase, weight decrease

4.5 Overdose and Treatment

For oral formulations:

In the event of acute overdosage with piroxicam (Feldene Flash), supportive and symptomatic therapy is indicated. There are no specific antidotes. Emesis and/or gastric lavage and/or activated charcoal may be considered dependent upon amount ingested and time since ingestion. Studies indicate that administration of activated charcoal may result in reduced absorption and re-absorption of piroxicam (Feldene Flash) thus reducing the total amount of active drug available.

Although there are no studies to date, hemodialysis is probably not useful in enhancing elimination of piroxicam (Feldene Flash) since the drug is highly protein-bound.

5.0 Shelf-Life

Two Years

6.0 How to Supplied:

Camroid Tablet 20mg: A carton containing Alu Alu blister strip of 20 tablets.

7.0 Storage Conditions/ Instruction:

Store at 30°C.
Protect form sunlight and moisture
Keep out of reach of children.

کیمرائیڈ ٹیبلیٹس
۲۰ ملی گرام

خوراک: ڈاکٹر کی ہدایت کے مطابق استعمال کریں۔

ہدایات:

۳۰ ڈگری پر محفوظ کریں۔

دھوپ اور نمی سے بچائیں۔ بچوں کی پہنچ سے دور رکھیں۔

صرف مسند ڈاکٹر کے نسخے پر فروخت کی جائے۔

MANUFACTURED BY:
 **NAWAN**
LABORATORIES (PVT) LTD.

136, Sector 15, Korangi Industrial
Area, Karachi-74900, Pakistan.